Retrolental fibroplasia: Further clinical evidence and ultrastructural support for efficacy of vitamin E in the preterm infant
Extract: To further evaluate the efficacy of oral vitamin E in preventing the development of severe retrolental fibroplasia (RLF) in very low-birthweight infants, 100 infants treated with 100 mg/kg/d of vitamin E (dl-alpha-tocopheryl acetate) were compared with 75 infants treated with 5 mg/kg/d of v...
Gespeichert in:
Veröffentlicht in: | Pediatrics (Evanston) 1983-03, Vol.71 (3), p.423-432 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Extract: To further evaluate the efficacy of oral vitamin E in preventing the development of severe retrolental fibroplasia (RLF) in very low-birthweight infants, 100 infants treated with 100 mg/kg/d of vitamin E (dl-alpha-tocopheryl acetate) were compared with 75 infants treated with 5 mg/kg/d of vitamin E (dl-alpha-tocopherol) in the same nursery during the previous year. All 175 infants weighed at or below 1/500 g at birth, and required supplemental oxygen. A total of 120 infants (69 treatment; 51 control) survived up to or longer than 10 weeks. Multivariate analysis of the control population identified 5 risk factors: gestational age, level and duration of oxygen administration, interventricular hemorrhage, sepsis, and birth weight. When multivariate analysis was applied to both control and treatment groups, the severity of RLF was found to be significantly reduced in infants given the treatment dose of vitamin E. Ultrastructural analyses of 58 pairs of whole-eye donations from high-risk infants surviving less than 10 weeks suggest that the initial morphologic event is gap junction increases between the plasma membranes of adjacent spindle cells of the vanguard retina. (author/wz) |
---|---|
ISSN: | 0031-4005 1098-4275 |
DOI: | 10.1542/peds.71.3.423 |